Our Vision
A society that values, respects and embraces diversity.
Our Mission
To work in partnership with targeted communities to promote health and well being that enhances the capacity of individuals to achieve quality of life and reach their full potential.
Our target communities include:
Guiding principles
1. Health and wellbeing doesn’t just include physical health, and includes mental and social health needs;
2. TasCAHRD aims to promote inclusive environments where people are able to reach their full potential;
3. TasCAHRD utilises a health promotion framework and harm reduction approach; and
4. TasCAHRD commits to ongoing continuous quality improvement.
Our Strategic Goals
1. Community Engagement and Capacity Building
TasCAHRD engages with the community on a variety of levels. This includes conducting projects in partnership with specific stakeholders as well as broader awareness-raising activities targeting the whole Tasmanian community. We work to support Tasmanian’s to develop greater capacity to respond to their own needs and make informed choices.
2. Responsiveness to Emerging Needs and Organisational Growth
TasCAHRD recognises that the HIV, sexual health, hepatitis and LGBTI health sectors are rapidly evolving sectors requiring organisational flexibility, resilience and the application of innovative responses to emerging needs
3. Shared Responsibilities and Collaborations
TasCAHRD recognises that working in partnership with the relevant community, individuals and other organisations is important for effective outcomes.
4. Client and Community Advocacy
The Ottawa Charter of Health Promotion highlights the importance of reducing barriers and creating enabling environments for target communities. As well as individual advocacy, systemic advocacy continue to be an important role for TasCAHRD.
5. Governance and Quality Service Delivery
TasCAHRD has strong foundations and established governance structures and is committed to continuous quality improvement. TasCAHRD will endeavour to build on this foundation to maximise its capacity to respond to issues affecting its target communities.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close